Group 1 - AMC Entertainment reported break-even quarterly earnings per share, compared to a loss of $0.43 per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $1.4 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.68%, and compared to year-ago revenues of $1.03 billion [2] - AMC Entertainment has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] Group 2 - The stock has lost about 26.4% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.08 on revenues of $1.31 billion, and for the current fiscal year, it is -$0.57 on revenues of $4.92 billion [7] - The Zacks Industry Rank indicates that the Leisure and Recreation Services sector is currently in the bottom 27% of over 250 Zacks industries, which may impact stock performance [8]

Group 1 - Great Lakes Dredge & Dock (GLDD) closed at $11.28, with a 0.8% gain over the past four weeks, and a mean price target of $15 indicates a 33% upside potential [1] - The mean estimate includes four short-term price targets with a standard deviation of $1.41, where the lowest estimate of $14.00 suggests a 24.1% increase, and the highest estimate of $17.00 indicates a potential surge of 50.7% [2] - Analysts show strong agreement on GLDD's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for GLDD's current year has increased by 3.5%, with one estimate moving higher and no negative revisions [12] - GLDD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While the consensus price target may not be entirely reliable, it provides a directional guide for potential price movement [14]

Core Viewpoint - Genmab A/S Sponsored ADR (GMAB) has seen a 3.8% increase in share price over the past four weeks, closing at $22.69, with a potential upside of 33.8% based on Wall Street analysts' mean price target of $30.36 [1] Price Targets - The average price target consists of seven estimates ranging from a low of $20.00 to a high of $46.00, with a standard deviation of $8.82, indicating variability among analysts [2] - The lowest estimate suggests an 11.9% decline from the current price, while the highest estimate indicates a 102.7% upside [2] Analyst Sentiment - Analysts show a consensus that GMAB will report better earnings than previously estimated, which historically correlates with stock price increases [4][11] - The Zacks Consensus Estimate for the current year has increased by 0.1% over the past month, with one estimate rising and no negative revisions [12] Zacks Rank - GMAB holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of GMAB's potential gains, it does provide a useful indication of the expected direction of price movement [14]

Company Performance - ANI Pharmaceuticals reported quarterly earnings of $1.8 per share, exceeding the Zacks Consensus Estimate of $1.38 per share, and up from $1.02 per share a year ago, representing an earnings surprise of +30.43% [1] - The company posted revenues of $211.37 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 12.22%, compared to year-ago revenues of $138.04 million [2] - Over the last four quarters, ANI has consistently surpassed consensus EPS and revenue estimates [2] Stock Movement and Outlook - ANI shares have increased approximately 24.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.8% [3] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.53 on revenues of $193.41 million, and for the current fiscal year, it is $6.55 on revenues of $789.84 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which ANI belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of ANI's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Gray Media (GTN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -82.61%. A quarter ago, it was expected that this broadcast television company would post a loss of $0.49 per share when it actually produced a loss of $0.23, delivering a surprise of +53.06%.Over the last four quarters, the ...

Company Performance - Inuvo, Inc (INUV) reported a quarterly loss of $0.1 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.11, representing an earnings surprise of +9.09% [1] - The company posted revenues of $22.67 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 6.4%, compared to year-ago revenues of $18.21 million [2] - Over the last four quarters, Inuvo has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - Inuvo shares have declined approximately 18.2% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The current Zacks Rank for Inuvo is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $27.96 million, and for the current fiscal year, it is -$0.05 on revenues of $107.7 million [7] - The trend of estimate revisions for Inuvo was unfavorable prior to the earnings release, which may impact future stock movements [5][6] Industry Context - The Internet - Services industry, to which Inuvo belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Group 1 - Lifecore Biomedical reported a quarterly loss of $0.1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of -11.11% [1] - The company posted revenues of $36.44 million for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 1.96%, but down from $37.89 million year-over-year [2] - Lifecore Biomedical has surpassed consensus revenue estimates three times over the last four quarters [2] Group 2 - The stock has added about 4% since the beginning of the year, underperforming the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the coming quarter is -$0.29 on revenues of $25.37 million, and -$0.61 on revenues of $132.88 million for the current fiscal year [7] Group 3 - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 41% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Lifecore Biomedical was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock [6]

Core Viewpoint - Forum Energy Technologies (FET) reported a quarterly loss of $0.1 per share, which was worse than the Zacks Consensus Estimate of $0.15, and compared to a loss of $0.07 per share a year ago [1][2] Financial Performance - The company posted revenues of $199.8 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.88%, but down from $205.2 million in the same quarter last year [3] - Over the last four quarters, Forum Energy has not surpassed consensus EPS estimates and has only topped consensus revenue estimates once [2][3] Stock Performance - Forum Energy shares have increased by approximately 20.9% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [4] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [7] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.48 on revenues of $195.47 million, and for the current fiscal year, it is $1.10 on revenues of $774.43 million [8] - The trend of estimate revisions for Forum Energy was unfavorable prior to the earnings release, which may impact future stock movements [6][7] Industry Context - Forum Energy operates within the Oil and Gas - Mechanical and Equipment industry, which is currently ranked in the top 41% of over 250 Zacks industries [9] - The performance of Forum Energy's stock may be influenced by the overall outlook for the industry [9]

Core Viewpoint - Portman Ridge (PTMN) reported quarterly earnings of $0.5 per share, exceeding the Zacks Consensus Estimate of $0.47 per share, but down from $0.7 per share a year ago, indicating a mixed performance trend [1][2] Financial Performance - The company posted revenues of $12.63 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.77%, but down from $16.34 million year-over-year [2] - Over the last four quarters, Portman Ridge has only surpassed consensus EPS estimates once and has topped consensus revenue estimates just once [2] Stock Performance - Portman Ridge shares have declined approximately 24.1% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.46 on revenues of $12.17 million, and for the current fiscal year, it is $1.99 on revenues of $48.62 million [7] - The trend of earnings estimate revisions is mixed ahead of the earnings release, which may influence future stock movements [6] Industry Context - The Financial - Investment Management industry, to which Portman Ridge belongs, is currently ranked in the top 23% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Performance - Zymeworks Inc. reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of a loss of $0.52 per share, and showing improvement from a loss of $0.26 per share a year ago, resulting in an earnings surprise of +105.77% [1] - The company achieved revenues of $48.73 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 256.65%, compared to revenues of $19.24 million in the same quarter last year [2] - Over the last four quarters, Zymeworks has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance - Zymeworks shares have declined approximately 15.2% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $27.89 million, and for the current fiscal year, it is -$1.64 on revenues of $100.05 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Zymeworks belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Zymeworks' stock performance [5]